The estimated Net Worth of John C Moore is at least $7.93 Milhão dollars as of 9 September 2020. Mr. Moore owns over 16,206 units of Staar Surgical Co stock worth over $555,370 and over the last 17 years he sold STAA stock worth over $7,188,341. In addition, he makes $190,272 as Independent Director at Staar Surgical Co.
Sign up
Mr. Moore STAA stock SEC Form 4 insiders trading
John has made over 13 trades of the Staar Surgical Co stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 16,206 units of STAA stock worth $228,343 on 9 September 2020.
The largest trade he's ever made was selling 137,331 units of Staar Surgical Co stock on 9 September 2020 worth over $7,146,705. On average, John trades about 8,045 units every 134 days since 2008. As of 9 September 2020 he still owns at least 18,323 units of Staar Surgical Co stock.
You can see the complete history of Mr. Moore stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Moore biography
John C. Moore serves as Independent Director of the Company. From December 2012 through December 2016, Mr. Moore served as a director and Chairperson of the Board of Directors of Optovue, Inc., an ophthalmic medical device company. From May 2014 through December 2018 Mr. Moore served as Chief Technical Officer of TearSolutions, Inc., a company focused on a natural replacement therapy for dry eyes. Since December 2018 he has served as a Board Observer at TearSolutions. Between April 2005 and January 2007, Mr. Moore served as Chief Executive Officer of Notal Vision, an Israel-based ophthalmic company that develops diagnostic solutions for the early detection and monitoring of age-related macular degeneration (AMD). Mr. Moore served as the President and Chief Executive Officer of Laser Diagnostic Technologies, a manufacturer of ophthalmic diagnostic laser devices used for the early detection of glaucoma, from 2000 until 2004 when it was acquired by Carl Zeiss Meditec, Inc. Before this, Mr. Moore was a vice president at Alcon Laboratories, one of the largest companies in the ophthalmic surgical sector, where he was responsible for pursuing and executing strategic acquisitions and partnerships to broaden that company’s product portfolio. Mr. Moore also spent more than 10 years in various leadership roles at Carl Zeiss, Inc., a multinational ophthalmic company with primary businesses in optics, medical, scientific and semiconductor products. Mr. Moore received his B.S. in General Science from University of Rochester. Qualifications. Mr. Moore’s extensive experience in the ophthalmic and medical device industries encompasses both large, well established companies and innovative start-ups.
What is the salary of John Moore?
As the Independent Director of Staar Surgical Co, the total compensation of John Moore at Staar Surgical Co is $190,272. There are 13 executives at Staar Surgical Co getting paid more, with Caren Mason having the highest compensation of $3,616,040.
How old is John Moore?
John Moore is 76, he's been the Independent Director of Staar Surgical Co since 2008. There are no older and 22 younger executives at Staar Surgical Co.
What's John Moore's mailing address?
John's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Insiders trading at Staar Surgical Co
Over the last 21 years, insiders at Staar Surgical Co have traded over $305,974,767 worth of Staar Surgical Co stock and bought 10,576,326 units worth $122,359,752 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Partners, L.P.Bradsher Neal..., eGilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of $1,643,742. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth $49,957.
What does Staar Surgical Co do?
staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad
What does Staar Surgical Co's logo look like?
Complete history of Mr. Moore stock trades at Staar Surgical Co
Staar Surgical Co executives and stock owners
Staar Surgical Co executives and other stock owners filed with the SEC include:
-
Caren Mason,
President, Chief Executive Officer, Director -
Scott Barnes,
Chief Medical Officer -
Keith Holliday,
Chief Technology Officer -
Caren L. Mason,
CEO, Pres & Director -
Hans-Martin Blickensdoerfer,
Senior Vice President - Commercial Operations, Direct Markets Europe and China -
Samuel Gesten,
Chief Legal Officer, Corporate Secretary -
Dr. Scott D. Barnes M.D.,
Chief Medical Officer -
James Francese,
Senior Vice President - Commercial Operations, North America and APAC -
Hans-Martin Blickensdoerfer,
Sr. VP of Commercial Operations and Director of Markets - Europe & China -
Dr. Keith Holliday,
Chief Technology Officer -
Patrick F. Williams,
Chief Financial Officer -
Louis Silverman,
Independent Chairman of the Board -
Stephen Farrell,
Independent Director -
John Moore,
Independent Director -
Patrick Williams,
Chief Financial Officer -
Gilbert Kliman,
Director -
Thomas Frinzi,
Director -
Brian Moore,
IR Contact Officer -
Jon Hayashida,
Vice President - Global Clinical and Medical Affairs -
Graydon Hansen,
Chief Manufacturing Officer and Senior Vice President, Global Operations -
Philippe Subrin,
VP of Collamer Lens Manufacturing & GM of Nidau Operations -
Joanne Egamino Ph.D.,
Global Head of Clinical Operations -
James Francese,
Sr. VP of Commercial Operations - North America & APAC -
William Goodmen,
VP of Global HR -
Samuel J. Gesten,
Chief Legal Officer & Corp. Sec. -
Lou Silverman,
Director -
Stephen P Brown,
Vice President & Chief Financi -
Richard A Meier,
Director -
Partners, L.P.Broadwood Cap...,
-
Partners, L.P.Bradsher Neal...,
-
William P Wall,
Director -
David Bailey,
President and CEO -
Robert Studholme,
Senior VP, Operations -
Wei Jiang,
-
Arthur C Butcher,
-
Nathaniel Sisitsky,
General Counsel -
Nicholas T Curtis,
Sr. VP Sales and Marketing -
Paul Hambrick,
Vice President, Operations -
Robert Kenneth Lally,
Vice President, QA/RA -
David L Schlotterbeck,
Director -
James I Farnworth,
VP Reg Affairs & Quality -
Gunther Roepstorff,
President - Domilens GmbH -
John R Gilbert,
Director -
Thomas R Paul,
Vice President - R & D -
John Bily,
Chief Financial Officer -
Volker D Anhaeusser,
Director -
John S Santos,
Sr. VP Planning & Corp Dev -
Jack Steven Roush,
-
Charles P Slacik,
Director -
Robin Hughes,
Vice President, Marketing -
Mark B Logan,
Director -
Barry G Caldwell,
Director -
Don M Bailey,
Director -
Kathryn Tunstall,
Director -
Philippe Subrin,
VP Switzerland OP -
Charles S Kaufman,
V.P. , General Counsel -
Donald J Todd,
President, Asia/Pacific -
Donald L Fagen,
V.P. Sales for N. America -
David R Morrison,
Director -
Craig Felberg,
VP, R&D and Clinical Affairs -
William Walter Goodmen,
Global VP, Human Resources -
Donald Duffy,
Director -
Isamu Kamijo,
President, STAAR Japan Inc. -
K Peony Yu,
Director -
Aimee S Weisner,
-
Magda Michna,
Chief Clinical, Regulatory, -
Warren Foust,
Chief Operating Officer -
Elizabeth Yeu Lin,
-
Lilian Yansheng Zhou,